Promises and paradoxes of regulatory T cells in inflammatory bowel disease.

@article{Lord2015PromisesAP,
  title={Promises and paradoxes of regulatory T cells in inflammatory bowel disease.},
  author={James D. Lord},
  journal={World journal of gastroenterology},
  year={2015},
  volume={21 40},
  pages={11236-45}
}
Since their discovery two decades ago, CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) have become the subject of intense investigation by immunologists. Unlike other T cells, which promote an immune response, Tregs actively inhibit inflammation when activated by their cognate antigen, thus raising hope that these cells could be engineered into a highly targeted, antigen-specific, immunosuppressant therapy. Although Tregs represent less than 10% of circulating CD4(+)T cells, they have been… CONTINUE READING